Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
08
12
2020
accepted:
01
04
2021
revised:
19
03
2021
pubmed:
18
4
2021
medline:
15
12
2021
entrez:
17
4
2021
Statut:
ppublish
Résumé
Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood. UK Biobank was used. Hormone concentrations were measured in serum collected in 2006-2010, and in a repeat subsample (N ~ 5000) in 2012-13. Incident cancers were identified through data linkage. Cox regression models were used, and hazard ratios (HRs) corrected for regression dilution bias. Among 30,565 pre-menopausal and 133,294 post-menopausal women, 527 and 2,997, respectively, were diagnosed with invasive breast cancer during a median follow-up of 7.1 years. Cancer risk was positively associated with testosterone in post-menopausal women (HR per 0.5 nmol/L increment: 1.18; 95% CI: 1.14, 1.23) but not in pre-menopausal women (p This study confirms associations of testosterone, IGF-1 and SHBG with breast cancer risk, with heterogeneity by menopausal status for testosterone.
Sections du résumé
BACKGROUND
Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood.
METHODS
UK Biobank was used. Hormone concentrations were measured in serum collected in 2006-2010, and in a repeat subsample (N ~ 5000) in 2012-13. Incident cancers were identified through data linkage. Cox regression models were used, and hazard ratios (HRs) corrected for regression dilution bias.
RESULTS
Among 30,565 pre-menopausal and 133,294 post-menopausal women, 527 and 2,997, respectively, were diagnosed with invasive breast cancer during a median follow-up of 7.1 years. Cancer risk was positively associated with testosterone in post-menopausal women (HR per 0.5 nmol/L increment: 1.18; 95% CI: 1.14, 1.23) but not in pre-menopausal women (p
CONCLUSIONS
This study confirms associations of testosterone, IGF-1 and SHBG with breast cancer risk, with heterogeneity by menopausal status for testosterone.
Identifiants
pubmed: 33864017
doi: 10.1038/s41416-021-01392-z
pii: 10.1038/s41416-021-01392-z
pmc: PMC8257641
doi:
Substances chimiques
IGF1 protein, human
0
SHBG protein, human
0
Sex Hormone-Binding Globulin
0
Testosterone
3XMK78S47O
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-134Subventions
Organisme : Medical Research Council
ID : G0700474
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 29186
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K02700X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9900923
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Cancer Research UK (CRUK)
ID : C570/A16491
Références
Henderson, B. E. & Feigelson, H. S. Hormonal carcinogenesis. Carcinogenesis 21, 427–433 (2000).
pubmed: 10688862
doi: 10.1093/carcin/21.3.427
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
pubmed: 30207593
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13, 1141–1151 (2012).
pmcid: 3488186
doi: 10.1016/S1470-2045(12)70425-4
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394, 1159–1168 (2019).
pmcid: 6891893
doi: 10.1016/S0140-6736(19)31709-X
Key, T. J., Appleby, P. N., Reeves, G. K., Travis, R. C., Brinton, L. A., Helzlsouer, K. J. et al. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. Steroids 99, 49–55 (2015).
pubmed: 25304359
doi: 10.1016/j.steroids.2014.09.001
Key, T. J., Appleby, P. N., Reeves, G. K., Travis, R. C., Alberg, A. J., Barricarte, A. et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 14, 1009–1019 (2013).
pubmed: 23890780
doi: 10.1016/S1470-2045(13)70301-2
Key, T., Appleby, P., Barnes, I. & Reeves, G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst. 94, 606–616 (2002).
pubmed: 11959894
doi: 10.1093/jnci/94.8.606
Key, T. J., Appleby, P. N., Reeves, G. K. & Roddam, A. W. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 11, 530–542 (2010).
pubmed: 20472501
doi: 10.1016/S1470-2045(10)70095-4
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M. et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am. J. Epidemiol. 150, 341–353 (1999).
pubmed: 10453810
doi: 10.1093/oxfordjournals.aje.a010013
MacMahon, S., Peto, R., Cutler, J., Collins, R., Sorlie, P., Neaton, J. et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335, 765–774 (1990).
pubmed: 1969518
doi: 10.1016/0140-6736(90)90878-9
Allen, N., Sudlow, C., Downey, P., Peakman, T., Danesh, J., Elliott, P. et al. UK Biobank: Current status and what it means for epidemiology. Health Policy Technol. 1, 123–126 (2012).
doi: 10.1016/j.hlpt.2012.07.003
Fry, D., Almond, R., Moffat, S., Gordon, M., Singh, P. UK Biobank Biomarker Project: Companion Document to Accompany Serum Biomarker Data 16p. http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=1227 . Accessed 8 Dec 2020 (2019).
Bartsch, W. Interrelationships between sex hormone-binding globulin and testosterone, 5α-dihydrotestosterone and oestradiol- 7β in blood of normal men. Maturitas 2, 109–118 (1980).
pubmed: 7193795
doi: 10.1016/0378-5122(80)90044-4
Vasiliou, S. K. & Diamandis, E. P. Androgen receptor: a promising therapeutic target in breast cancer. Crit. Rev. Clin. Lab Sci. 56, 200–223 (2019).
pubmed: 30821186
doi: 10.1080/10408363.2019.1575643
Davis, S. R. & Wahlin-Jacobsen, S. Testosterone in women—the clinical significance. Lancet Diabet. Endocrinol. 3, 980–992 (2015).
doi: 10.1016/S2213-8587(15)00284-3
Thaler, M. A., Seifert-Klauss, V. & Luppa, P. B. The biomarker sex hormone-binding globulin – From established applications to emerging trends in clinical medicine. Best Pr. Res Clin. Endocrinol. Metab. 29, 749–760 (2015).
doi: 10.1016/j.beem.2015.06.005
Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915–928 (2008).
pubmed: 19029956
doi: 10.1038/nrc2536
Ruan, W., Catanese, V., Wieczorek, R., Feldman, M. & Kleinberg, D. L. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 136, 1296–1302 (1995).
pubmed: 7867584
doi: 10.1210/endo.136.3.7867584
Hawsawi, Y., El-Gendy, R., Twelves, C., Speirs, V. & Beattie, J. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. Biochim. Biophys. Acta 1836, 345–353 (2013).
pubmed: 24189571
Murphy, N., Knuppel, A., Papadimitriou, N., Martin, R. M., Tsilidis, K. K., Smith-Byrne, K. et al. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women. Ann. Oncol. 31, 641–649 (2020).
pubmed: 32169310
doi: 10.1016/j.annonc.2020.01.066
Monson, K. R., Goldberg, M., Wu, H.-C., Santella, R. M., Chung, W. K. & Terry, M. B. Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort. Breast Cancer Res. 22, 109 (2020).
pubmed: 33092613
pmcid: 7579807
doi: 10.1186/s13058-020-01352-0
Brown, S. B. & Hankinson, S. E. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 99, 8–10 (2015).
pubmed: 25555473
doi: 10.1016/j.steroids.2014.12.013
Atashgaran, V., Wrin, J., Barry, S. C., Dasari, P. & Ingman, W. V. Dissecting the biology of menstrual cycle-associated breast cancer risk. Front. Oncol. 6, 267–267 (2016).
pubmed: 28083513
pmcid: 5183603
doi: 10.3389/fonc.2016.00267
Newman, J. D. & Handelsman, D. J. Challenges to the measurement of oestradiol: comments on an endocrine society position statement. Clin. Biochem. Rev. 35, 75–79 (2014).
pubmed: 25210207
pmcid: 4159782
Stricker, R., Eberhart, R., Chevailler, M. C., Quinn, F. A., Bischof, P. & Stricker, R. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin. Chem. Lab. Med. 44, 883–887 (2006).
pubmed: 16776638
doi: 10.1515/CCLM.2006.160
McIntosh, J. E., Matthews, C. D., Crocker, J. M., Broom, T. J. & Cox, L. W. Predicting the luteinizing hormone surge: relationship between the duration of the follicular and luteal phases and the length of the human menstrual cycle. Fertil. Steril. 34, 125–130 (1980).
pubmed: 7409231
doi: 10.1016/S0015-0282(16)44894-6
Tin Tin, S., Reeves, G. K. & Key, T. J. Body size and composition, physical activity and sedentary time in relation to endogenous hormones in premenopausal and postmenopausal women: Findings from the UK Biobank. Int J. Cancer 147, 2101–2115 (2020).
pubmed: 32285445
doi: 10.1002/ijc.33010
Houghton, L. C., Ganmaa, D., Rosenberg, P. S., Davaalkham, D., Stanczyk, F. Z., Hoover, R. N. et al. Associations of breast cancer risk factors with premenopausal sex hormones in women with very low breast cancer risk. Int. J. Environ Res. Public Health 13, 1066 (2016)
Key, T. J., Appleby, P. N., Reeves, G. K., Roddam, A. W., Helzlsouer, K. J., Alberg, A. J. et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br. J. Cancer 105, 709–722 (2011).
pubmed: 21772329
doi: 10.1038/bjc.2011.254
Ruth, K. S., Day, F. R., Tyrrell, J., Thompson, D. J., Wood, A. R., Mahajan, A. et al. Using human genetics to understand the disease impacts of testosterone in men and women. Nat. Med. 26, 252–258 (2020).
pubmed: 32042192
pmcid: 7025895
doi: 10.1038/s41591-020-0751-5
Dimou, N. L., Papadimitriou, N., Gill, D., Christakoudi, S., Murphy, N., Gunter, M. J. et al. Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. Int. J. Epidemiol. 48, 807–816 (2019).
pubmed: 31143958
pmcid: 6659370
doi: 10.1093/ije/dyz107
Nelson, H. D., Fu, R., Zakher, B., Pappas, M. & McDonagh, M. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 322, 868–886 (2019).
pubmed: 31479143
doi: 10.1001/jama.2019.5780
Cuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381, 1827–1834 (2013).
pubmed: 23639488
pmcid: 3671272
doi: 10.1016/S0140-6736(13)60140-3
Louro, J., Posso, M., Hilton Boon, M., Román, M., Domingo, L., Castells, X. et al. A systematic review and quality assessment of individualised breast cancer risk prediction models. Br. J. Cancer 121, 76–85 (2019).
pubmed: 31114019
pmcid: 6738106
doi: 10.1038/s41416-019-0476-8
Clendenen, T. V., Ge, W., Koenig, K. L., Afanasyeva, Y., Agnoli, C., Brinton, L. A. et al. Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Res. 21, 42–42 (2019).
pubmed: 30890167
pmcid: 6425605
doi: 10.1186/s13058-019-1126-z
Zhang, X., Rice, M., Tworoger, S. S., Rosner, B. A., Eliassen, A. H., Tamimi, R. M. et al. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: a nested case–control study. PLoS Med. 15, e1002644 (2018).
pubmed: 30180161
pmcid: 6122802
doi: 10.1371/journal.pmed.1002644
Hüsing, A., Fortner, R. T., Kühn, T., Overvad, K., Tjønneland, A., Olsen, A. et al. Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: Results from the EPIC cohort. Clin. Cancer Res. 23, 4181–4189 (2017).
pubmed: 28246273
doi: 10.1158/1078-0432.CCR-16-3011
Møller, H., Richards, S., Hanchett, N., Riaz, S. P., Lüchtenborg, M., Holmberg, L. et al. Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates. Br. J. Cancer 105, 170–176 (2011).
pubmed: 21559016
pmcid: 3137398
doi: 10.1038/bjc.2011.168